ative to the U.S. dollar could materially, adversely impact our business, rapid technological change could cause our products and services to become obsolete, and we are dependent on key personnel. Our expectations regarding earnings per share for 2013 include anticipated 2013 expenses for research and development
In the event that research and development expenses are higher than expected, our actual 2013 earnings per share would be lower than projected. These risks and uncertainties include the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for the year ended December 31, 2012, and our subsequent filings with the SEC. CryoLife does not undertake to update its forward-looking statements.
For additional information about CryoLife, visit CryoLife's website, www.cryolife.com.
CRYOLIFE, INC. AND SUBSIDIARIESFinancial Highlights(In thousands, except per share data) Three Months EndedSix Months EndedJune 30,June 30,2013201220132012(Unaudited)(Unaudited)Revenues:Products
33,150Preservation services15,31716,31330,99431,972Other817971367Total revenues33,52033,18869,05665,489Cost of products and preservation services:Products3,7212,6737,1865,186Preservation services8,3209,14417,11517,640Total cost of products andpreservation services12,04111,81724,30122,826Gross margin21,47921,37144,75542,663Operating expenses:General, administrative, and marketing16,93213,87134,90931,841Research and development1,7361,6703,7243,363Total operating expenses18,66815,54138,63335,204Operating income2,8115,8306,1227,459Interest expense5452104117Interest income--(1)(2)(3)Other expense, net22174241159Income before income taxes2,7355,6055,7797,186Income tax expense9502,2711,8022,861Net income$1,785$3,334$3,977$4,325Income per common share:Basic$0.06$0.12$0.14$0.16Diluted$Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Related medicine technology :1
. CryoLife Announces Release Date and Teleconference Call Details for 2013 Second Quarter Financial Results2
. CryoLife Enhances International Presence with Appointment of Andres Sarmiento as Latin America Sales Manager3
. CryoLife 2013 First Quarter Revenues Grew 10 Percent to a Record $35.5 Million4
. CryoLife Announces Release Date and Teleconference Call Details for 2013 First Quarter Financial Results5
. CryoLife Receives FDA Clearance For Next Generation HeRO Device6
. CryoLife Expands Stock Repurchase Program7
. CryoLife 2012 Annual Revenues Grew to a Record $131.7 Million8
. CryoLife Announces Quarterly Cash Dividend for the First Quarter 20139
. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results10
. CryoLife Receives Expanded Indication for BioFoam in Europe11
. CryoLife to Participate in Lazard Capital Markets 9th Annual Healthcare Conference